CANDEL THERAPEUTICS INC. - COMMON STOCK

Candel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

05 Aug 2022 07:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics Announces Release of Initial Data on CAN-2409 in a Phase 2 Clinical Trial Showing Cytotoxic T Cell Response and Disease Control in Patients with Non-Small Cell Lung Cancer

26 May 2022 16:30:00 By Nasdaq GlobeNewswire

Candel Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

18 May 2022 07:00:01 By Nasdaq GlobeNewswire

Candel Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

12 May 2022 07:00:02 By Nasdaq GlobeNewswire

Candel Therapeutics to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

27 Apr 2022 15:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Highlights

29 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Candel Therapeutics Appoints Seshu Tyagarajan, Ph.D., RAC, as Chief Technical and Development Officer

02 Mar 2022 07:00:02 By Nasdaq GlobeNewswire

Candel Therapeutics Announces $25 Million Non-dilutive Debt Financing Agreement with Silicon Valley Bank

01 Mar 2022 07:00:02 By Nasdaq GlobeNewswire

Candel Therapeutics Appoints Dr. Francesca Barone as Chief Scientific Officer

03 Feb 2022 07:00:01 By Nasdaq GlobeNewswire

Candel Therapeutics to Present at Two Upcoming Investor Conferences

05 Jan 2022 07:00:02 By Nasdaq GlobeNewswire

Bionaut Labs and Candel Therapeutics Announce Strategic Collaboration in Precision-Targeted Delivery of Oncolytic Viral Immunotherapies

15 Dec 2021 04:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics and Partnership for Accelerating Cancer Therapies (PACT) to Collaborate on Lung Cancer Trial for CAN-2409

10 Dec 2021 07:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights

12 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

Candel Therapeutics Presents Novel Biomarker Data Demonstrating Immune Activation After Administration of CAN-3110 in Patients with Recurrent High-Grade Glioma

12 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

Candel Therapeutics to Participate in Three Upcoming Investor Conferences

02 Nov 2021 07:00:03 By Nasdaq GlobeNewswire

Candel Therapeutics Announces Upcoming Data Presentations on its Oncolytic Viral Immunotherapies

01 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

Candel Therapeutics Announces Patient-Reported Tolerability Data of Intraprostatic Injections in Ongoing Phase 3 Clinical Trial of CAN-2409 in Patients with Localized Prostate Cancer 

28 Oct 2021 07:00:01 By Nasdaq GlobeNewswire

Candel Therapeutics Appoints Mace L. Rothenberg, MD, as Senior Advisor to the Chief Executive Officer

19 Oct 2021 07:00:02 By Nasdaq GlobeNewswire

Candel Therapeutics Announces Participation in Upcoming Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

04 Oct 2021 07:00:01 By Nasdaq GlobeNewswire

Candel Therapeutics Announces Participation in Upcoming Scientific Conferences Related to Oncolytic Viral Immunotherapies

01 Oct 2021 07:00:01 By Nasdaq GlobeNewswire